Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 2/20 | 0.33 |
| ▸ | PPARA | Q07869 | 2/20 | 0.33 |
| ▸ | HPGDS | O60760 | 1/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.31 |
| ▸ | DRD4 | P21917 | 4/20 | 0.31 |
| ▸ | DRD2 | P14416 | 3/20 | 0.31 |
| ▸ | HTR2A | P28223 | 2/20 | 0.31 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.31 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5870406 | 0.88 | NAAA (0.41) | CTSSCTSK | |
| SCHEMBL5870529 | 0.84 | PPARA (0.39) | HDAC1HDAC6CDK2SRCPPARG | |
| SCHEMBL5870628 | 0.83 | GRIA2 (0.35) | HDAC1HDAC6CDK2SRCPPARG | |
| SCHEMBL6962186 | 0.79 | OPRD1 (0.37) | — | |
| SCHEMBL5870421 | 0.77 | CTSK (0.35) | CTSK | |
| SCHEMBL5870275 | 0.71 | CTSC (0.43) | ADAM17CTSLCTSSCTSK | |
| SCHEMBL5870300 | 0.70 | NAAA (0.41) | CTSLCTSSCTSK | |
| SCHEMBL5870549 | 0.67 | CTSL (0.37) | CTSLCTSSCTSK | |
| SCHEMBL5870460 | 0.66 | ME2 (0.36) | PPARGPPARACTSLCTSK | |
| SCHEMBL5870399 | 0.66 | PSMB5 (0.47) | CTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7132449-B2 | Inhibitors of cruzipain and other cysteine proteases | AMURA THERAPEUTICS LIMITED (GB) | 2006-11-07 | — | — | US | disclosed |
| US-20040127424-A1 | Inhibitors of cruzipain and other cysteine proteases | AMURA THERAPUTICS LIMITED (GB) | 2004-07-01 | — | — | US | disclosed |
| EP-1358174-A2 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | Amura Therapeutics Limited (GB) | 2003-11-05 | — | — | EP | disclosed |
| WO-2002057248-A2 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | AMURA THERAPEUTICS LIMITED (GB) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127424-A1 | Inhibitors of cruzipain and other cysteine proteases | CPN1, CTRL, CPA1 | HDAC1 993/4885HDAC6 1175/4885CDK2 1138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.